Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are reported to reduce body fat in patients with type 2 diabetes mellitus (T2DM), and SGLT2i-induced weight reduction may help improve comorbid nonalcoholic fatty liver disease (NAFLD). This study aimed to investigate the potential benefit of SGLT2...

Full description

Bibliographic Details
Main Authors: Won Euh, Soo Lim, Jin-Wook Kim
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Endocrinology
Subjects:
type 2 diabetes mellitus
sodium-glucose cotransporter 2 (SGLT2) inhibitor
alanine aminotransferase
body weight
propensity score (PS) matching (PSM)
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2021.613389/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2021.613389/full

Similar Items